Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Revenue (2016 - 2025)

Historic Revenue for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $134.2 million.

  • Adma Biologics' Revenue rose 1200.36% to $134.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $488.6 million, marking a year-over-year increase of 2762.47%. This contributed to the annual value of $426.5 million for FY2024, which is 6515.46% up from last year.
  • Adma Biologics' Revenue amounted to $134.2 million in Q3 2025, which was up 1200.36% from $122.0 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Revenue peaked at $134.2 million during Q3 2025, and registered a low of $16.0 million during Q1 2021.
  • Over the past 5 years, Adma Biologics' median Revenue value was $73.9 million (recorded in 2023), while the average stood at $73.8 million.
  • As far as peak fluctuations go, Adma Biologics' Revenue skyrocketed by 32062.55% in 2022, and later plummeted by 1983.6% in 2023.
  • Quarter analysis of 5 years shows Adma Biologics' Revenue stood at $55.0 million in 2021, then dropped by 9.12% to $50.0 million in 2022, then surged by 47.86% to $73.9 million in 2023, then skyrocketed by 59.06% to $117.5 million in 2024, then increased by 14.19% to $134.2 million in 2025.
  • Its last three reported values are $134.2 million in Q3 2025, $122.0 million for Q2 2025, and $114.8 million during Q1 2025.